1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Mosbah, A. Marrakchi, N. Ganzalez, M.J. Van Rietschoten, J. Giralt, E. El Ayeb, M. Rochat, H. Sabatier, J.M. Darbon, H. Mabrouk, K. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Lebetin peptides, a new class of potent aggregation inhibitors 10.2210/pdb1q01/pdb pdb_00001q01 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 3954.437 lebetin 2 isoform alpha 1 nat polymer no no GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n Levantine viper Macrovipera sample 8709 Macrovipera lebetina venom database_2 pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2005-05-03 1 1 2008-04-29 1 2 2011-07-13 1 3 2022-03-02 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_software.name N RCSB Y RCSB 2003-07-15 REL back calculated data agree with experimental NOESY spectrum,structures with acceptable covalent geometry,structures with favorable non-bond energy,structures with the least restraint violations,structures with the lowest energy,target function 50 24 DQF-COSY 2D TOCSY 2D NOESY DQF-COSY 2D TOCSY 2D NOESY 3 ambient 280 K 3 ambient 283 K Diana and CNS, distance geometry, simulated annealing 1 fewest violations, lowest energy 90% H2O, 10% D2O 90% H2O, 10% D2O collection XwinNMR processing XwinNMR data analysis XEASY structure solution DIANA refinement CNS 500 Bruker DRX GLY 1 n 1 GLY 1 A ASP 2 n 2 ASP 2 A ASN 3 n 3 ASN 3 A LYS 4 n 4 LYS 4 A PRO 5 n 5 PRO 5 A PRO 6 n 6 PRO 6 A LYS 7 n 7 LYS 7 A LYS 8 n 8 LYS 8 A GLY 9 n 9 GLY 9 A PRO 10 n 10 PRO 10 A PRO 11 n 11 PRO 11 A ASN 12 n 12 ASN 12 A GLY 13 n 13 GLY 13 A CYS 14 n 14 CYS 14 A PHE 15 n 15 PHE 15 A GLY 16 n 16 GLY 16 A HIS 17 n 17 HIS 17 A LYS 18 n 18 LYS 18 A ILE 19 n 19 ILE 19 A ASP 20 n 20 ASP 20 A ARG 21 n 21 ARG 21 A ILE 22 n 22 ILE 22 A GLY 23 n 23 GLY 23 A SER 24 n 24 SER 24 A HIS 25 n 25 HIS 25 A SER 26 n 26 SER 26 A GLY 27 n 27 GLY 27 A LEU 28 n 28 LEU 28 A GLY 29 n 29 GLY 29 A CYS 30 n 30 CYS 30 A ASN 31 n 31 ASN 31 A LYS 32 n 32 LYS 32 A VAL 33 n 33 VAL 33 A ASP 34 n 34 ASP 34 A ASP 35 n 35 ASP 35 A ASN 36 n 36 ASN 36 A LYS 37 n 37 LYS 37 A GLY 38 n 38 GLY 38 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A ASP 2 68.49 -68.10 1 A LYS 8 -51.14 178.55 1 A PRO 11 -69.98 63.34 1 A ASN 12 61.24 112.90 1 A CYS 14 -57.65 -164.91 1 A LYS 18 -90.81 49.30 1 A ILE 22 54.51 173.83 2 A LYS 4 -108.40 77.01 2 A LYS 7 59.70 161.53 2 A ASN 12 -165.48 -168.29 2 A CYS 14 60.65 156.67 2 A LYS 18 74.90 96.18 2 A ASP 20 58.46 160.82 2 A ILE 22 54.58 173.61 2 A ASN 31 -56.57 -178.71 2 A LYS 32 59.87 73.60 2 A ASP 34 -105.36 56.42 2 A ASN 36 66.10 -73.64 2 A LYS 37 -175.15 -41.78 3 A ASP 2 -153.90 80.59 3 A ASN 12 -179.62 -178.48 3 A PHE 15 -59.07 -178.33 3 A HIS 17 -56.06 -178.29 3 A LYS 18 -88.04 48.82 3 A ASP 20 54.82 105.31 3 A LEU 28 -47.17 170.67 3 A ASP 34 -69.94 61.76 3 A ASN 36 -50.74 97.01 4 A ASN 3 -162.92 93.07 4 A LYS 4 -59.13 109.25 4 A ASN 12 43.41 91.97 4 A PHE 15 -59.69 171.96 4 A LYS 18 -90.73 48.68 4 A SER 24 -59.74 -74.76 4 A LEU 28 -52.43 -178.45 4 A CYS 30 -126.33 -53.38 4 A LYS 32 -60.04 92.84 5 A PRO 11 -69.84 84.17 5 A PHE 15 -52.67 -179.03 5 A LYS 18 -90.90 48.95 5 A HIS 25 -124.35 -61.67 5 A LEU 28 -55.25 170.78 5 A CYS 30 -149.09 -53.75 5 A ASN 36 65.83 -73.44 6 A PRO 11 -69.91 84.25 6 A CYS 14 52.63 177.75 6 A LYS 18 166.92 99.26 6 A ASP 20 56.36 162.78 6 A ILE 22 -42.20 161.02 6 A LEU 28 -67.35 -174.75 6 A ASP 34 -112.27 54.13 6 A ASP 35 63.89 -65.82 7 A ASP 2 -103.04 -65.77 7 A ASN 3 -151.98 -46.89 7 A LYS 7 61.30 111.52 7 A ASN 12 179.91 158.74 7 A PHE 15 -47.39 151.67 7 A HIS 17 -59.04 178.77 7 A LYS 18 74.82 84.18 7 A ASP 20 59.50 159.96 7 A ILE 22 54.67 173.58 7 A HIS 25 -123.07 -59.08 7 A CYS 30 -102.05 -74.33 7 A ASP 35 -67.41 97.57 7 A LYS 37 59.99 85.69 8 A ASP 2 60.20 83.27 8 A ASN 12 178.53 -35.39 8 A LYS 18 75.57 96.82 8 A ASP 20 50.32 99.14 8 A ILE 22 54.60 173.72 8 A CYS 30 -129.99 -75.30 8 A ASN 31 -61.36 -179.17 8 A ASP 35 -92.67 -65.75 8 A ASN 36 -50.93 104.00 9 A ASP 2 -175.94 -53.63 9 A ASN 3 -161.48 93.65 9 A LYS 4 -59.29 109.58 9 A LYS 8 -56.50 172.67 9 A ASN 12 -177.48 116.81 9 A CYS 14 47.24 -174.25 9 A LYS 18 77.04 97.33 9 A ASP 20 46.71 94.62 9 A ARG 21 -56.30 89.08 9 A ILE 22 54.34 173.47 9 A SER 24 -122.44 -82.18 9 A HIS 25 -120.22 -52.23 9 A SER 26 -49.46 172.78 9 A LEU 28 -52.66 170.68 9 A ASN 31 -56.37 -179.06 9 A ASP 35 -151.05 -47.21 9 A LYS 37 60.47 80.29 10 A ASP 2 63.37 -78.76 10 A ASN 3 74.55 -54.14 10 A PRO 11 -69.71 92.18 10 A ASN 12 176.41 -34.33 10 A CYS 14 60.26 157.71 10 A HIS 17 -58.14 172.82 10 A LYS 18 -91.95 49.34 10 A ILE 22 54.78 173.70 10 A CYS 30 -109.02 -71.11 10 A ASP 34 -141.89 59.81 10 A ASP 35 -151.69 -45.99 10 A ASN 36 -50.68 176.01 11 A LYS 4 -59.51 109.98 11 A PRO 11 -69.84 83.79 11 A ASN 12 -165.60 32.61 11 A HIS 17 -56.57 173.96 11 A LYS 18 -91.56 49.63 11 A ILE 22 54.55 174.28 11 A LEU 28 -60.26 -174.94 11 A CYS 30 -143.91 -47.21 11 A ASN 31 -69.21 -179.08 11 A LYS 32 -60.46 95.49 12 A ASN 3 -176.64 -55.50 12 A LYS 7 -150.78 76.69 12 A ASN 12 59.89 109.18 12 A CYS 14 -122.65 -95.59 12 A HIS 17 -56.46 173.13 12 A SER 24 -167.81 -68.53 12 A HIS 25 -125.90 -59.16 12 A LYS 32 -176.16 79.30 12 A ASP 34 -106.59 56.58 12 A ASN 36 65.80 -73.58 12 A LYS 37 -176.16 -59.94 13 A LYS 4 -59.35 109.63 13 A ASN 12 60.26 109.61 13 A CYS 14 60.78 156.70 13 A PHE 15 -55.27 -179.48 13 A LYS 18 77.53 98.46 13 A ASP 20 58.26 161.60 13 A ILE 22 -41.30 161.91 13 A LYS 32 -176.78 79.42 13 A ASN 36 176.39 101.54 13 A LYS 37 60.59 95.67 14 A ASP 2 68.49 -68.17 14 A LYS 8 -51.22 178.70 14 A ASN 12 61.25 112.97 14 A CYS 14 -57.88 -164.76 14 A LYS 18 -92.08 48.96 14 A ILE 22 54.92 173.76 15 A ASN 3 -117.83 71.58 15 A LYS 4 -59.35 109.57 15 A PRO 11 -69.97 63.59 15 A CYS 14 -122.46 -95.44 15 A HIS 17 -59.32 175.53 15 A LYS 18 -94.25 39.58 15 A ASP 20 -51.19 109.98 15 A ILE 22 54.50 174.77 15 A HIS 25 -100.09 -73.60 15 A SER 26 55.60 171.61 15 A ASN 36 66.10 -73.90 16 A ASP 2 60.64 88.29 16 A LYS 7 -61.00 91.33 16 A ASN 12 60.26 84.33 16 A PHE 15 -53.17 -178.75 16 A LYS 18 -91.04 48.63 16 A ILE 22 54.68 173.96 16 A LEU 28 -56.07 170.58 16 A CYS 30 -147.89 -57.11 16 A ASN 31 -58.92 172.36 16 A LYS 32 56.40 79.23 16 A ASP 35 -92.36 -72.13 16 A ASN 36 60.34 158.52 17 A ASP 2 64.07 -79.14 17 A CYS 14 51.04 179.22 17 A HIS 17 -56.56 -179.59 17 A LYS 18 -88.64 48.23 17 A ASP 20 46.31 92.23 17 A ILE 22 54.85 173.93 17 A SER 24 -66.73 -79.66 17 A HIS 25 -126.83 -57.40 17 A SER 26 -57.83 172.69 17 A LYS 32 -176.48 110.52 17 A ASP 34 -69.80 62.79 17 A ASN 36 -49.65 175.53 17 A LYS 37 -176.53 -41.36 18 A LYS 8 -59.78 173.53 18 A PRO 11 -69.31 62.99 18 A HIS 17 -57.47 -177.75 18 A LYS 18 -85.35 46.55 18 A ILE 19 -98.23 -64.18 18 A ASP 20 42.70 92.74 18 A ILE 22 54.81 173.53 18 A SER 24 -56.92 -79.07 18 A HIS 25 -137.83 -64.11 18 A SER 26 -49.43 172.67 18 A CYS 30 -129.68 -66.52 18 A ASP 35 -145.25 -47.26 18 A ASN 36 -49.97 158.45 18 A LYS 37 63.72 -79.43 19 A ASP 2 68.24 -69.98 19 A PRO 11 -69.35 77.92 19 A ASN 12 -177.47 112.93 19 A CYS 14 -58.50 -164.29 19 A PHE 15 -49.93 166.29 19 A HIS 17 -56.52 -178.99 19 A LYS 18 -92.54 40.19 19 A ASP 20 -61.46 95.07 19 A SER 24 -107.20 -79.26 19 A HIS 25 -139.87 -65.52 19 A SER 26 -52.33 172.17 19 A ASN 31 -50.40 175.52 19 A ASP 34 -99.22 59.98 19 A ASN 36 -50.76 172.05 20 A ASP 2 68.10 -69.81 20 A ASN 3 -118.04 71.42 20 A LYS 4 -59.21 109.89 20 A PRO 11 -69.80 84.48 20 A ASN 12 45.44 -168.74 20 A PHE 15 -60.01 -179.20 20 A LYS 18 -97.02 41.12 20 A ILE 22 54.48 173.73 20 A SER 24 -118.32 -81.54 20 A SER 26 -59.90 172.03 20 A LEU 28 -59.59 178.49 20 A LYS 32 -172.73 89.50 20 A ASN 36 65.66 -73.39 21 A ASP 2 60.63 163.90 21 A ASN 12 -60.11 88.31 21 A HIS 17 -59.72 178.90 21 A LYS 18 -87.79 47.19 21 A ILE 19 -109.64 -71.05 21 A ASP 20 40.44 93.52 21 A ARG 21 -59.57 89.96 21 A ILE 22 57.00 173.51 21 A SER 26 -48.56 156.48 21 A CYS 30 -152.54 -56.88 21 A ASN 31 -54.85 -178.65 21 A LYS 32 -56.95 101.36 21 A ASN 36 -51.20 101.34 22 A ASN 3 -117.89 71.18 22 A CYS 14 61.37 157.02 22 A LYS 18 -95.69 38.58 22 A ARG 21 -59.05 170.01 22 A ILE 22 -44.89 164.51 22 A ASP 34 56.30 75.49 22 A ASP 35 -151.64 -46.84 23 A ASP 2 60.45 104.59 23 A PRO 11 -69.99 92.80 23 A LYS 18 -90.80 49.17 23 A ARG 21 -100.21 77.67 23 A SER 24 -131.48 -68.86 23 A ASP 34 -91.97 56.45 23 A LYS 37 60.50 110.82 24 A ASP 2 -176.42 146.49 24 A ASN 3 -98.88 31.79 24 A LYS 4 -59.46 109.82 24 A ASN 12 -164.89 31.77 24 A LYS 18 -96.73 38.26 24 A ARG 21 -58.87 170.88 24 A ILE 22 -46.27 166.82 24 A CYS 30 -158.29 -46.54 24 A ASN 31 -59.99 -179.55 24 A LYS 32 -59.99 98.36 24 A ASN 36 -50.65 96.25 Lebetin peptides, a new class of potent aggregation inhibitors 1 N N disulf 2.029 A CYS 14 A SG CYS 14 1_555 A CYS 30 A SG CYS 30 1_555 BLOOD CLOTTING BETA-BULGED HAIRPAIN, BLOOD CLOTTING Q7LZ09_VIPLE UNP 1 1 Q7LZ09 GDNKPPKKGPPNGCFGHKIDRIGSHSGLGCNKVDDNKG 1 38 1Q01 1 38 Q7LZ09 A 1 1 38